Brokers Offer Predictions for Skye Bioscience Q1 Earnings

Skye Bioscience, Inc. (NASDAQ:SKYE) – Equities researchers at William Blair issued their Q1 2026 earnings estimates for shares of Skye Bioscience in a research report issued on Tuesday, April 15th. William Blair analyst A. Hsieh forecasts that the company will earn ($0.33) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Skye Bioscience’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Skye Bioscience’s Q3 2026 earnings at ($0.32) EPS and Q4 2026 earnings at ($0.31) EPS.

Skye Bioscience (NASDAQ:SKYE) last issued its earnings results on Thursday, March 20th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. During the same period last year, the company posted ($0.36) earnings per share.

Separately, Craig Hallum lowered their price objective on shares of Skye Bioscience from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $16.60.

Skye Bioscience Trading Down 9.2 %

Shares of NASDAQ SKYE opened at $1.44 on Thursday. The company has a market cap of $44.45 million, a price-to-earnings ratio of -1.99 and a beta of 1.88. Skye Bioscience has a 12 month low of $1.14 and a 12 month high of $17.40. The stock has a 50-day moving average price of $1.64 and a two-hundred day moving average price of $2.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SKYE. BNP Paribas Financial Markets lifted its holdings in Skye Bioscience by 71.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,417 shares of the company’s stock worth $185,000 after buying an additional 19,704 shares during the period. Jane Street Group LLC acquired a new position in shares of Skye Bioscience in the third quarter worth approximately $48,000. Geode Capital Management LLC lifted its stake in shares of Skye Bioscience by 4.2% in the third quarter. Geode Capital Management LLC now owns 385,793 shares of the company’s stock worth $1,509,000 after acquiring an additional 15,614 shares during the period. Barclays PLC increased its position in Skye Bioscience by 36.7% during the 3rd quarter. Barclays PLC now owns 57,889 shares of the company’s stock valued at $226,000 after purchasing an additional 15,551 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Skye Bioscience by 20.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 62,363 shares of the company’s stock worth $176,000 after purchasing an additional 10,707 shares during the last quarter. Institutional investors and hedge funds own 21.09% of the company’s stock.

About Skye Bioscience

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.